While Web3 is widely known for its promise in decentralization & transparency, Cathay’s Denis Barrier explores how it could also be the highway for a safer AI revolution… […]
A New Intelligence Infrastructure: Where AI, Web3 & Cybersecurity Converge
Beem beams in €20M to help European homes better manage energy with its DIY solar panels
[…]
Policy: The Least Spoken About, But Most Important Topic in Artificial Intelligence
Cathay Partner Rajive Keshup digs into the multifaceted nature of AI technologies, their impact on society and the compelling reasons why we need thoughtful and balanced regulations in place… […]
5 investors discuss what’s in store for venture debt following SVB’s collapse
Cathay Innovation’s SF-based Partner Simon Wu weighs in… […]
Reality vs. Hype: How AI & Human Activity Combine
AI-driven startups across the world weigh in on the impact of the AI revolution on businesses & industries […]
Exploring the rise of finance-as-a-service in APAC
Cathay’s Singapore-based investor Rensyn Hooi digs into the rise of finance-as-a-service and the unique opportunity in APAC for startups providing the infrastructure needed to accelerate fintechs across the region. […]
Industry Insights: How Will AI Impact the Modern-Day Education System?
Cathay’s SEA-based Partner Rajive Keshup weighs in on the VC-parent perspective on the potential & limitations of AI in educating the next generations… […]
Reduce, Reuse…Recommerce? Why Recommerce is the New Black
Cathay’s SF-based investor Brian Schwarzbach digs into what’s driving the recommerce resurgence, top areas drawing VC investment and tips for founders building in the space… […]
VCs to recommerce startups: Let’s pop some tags
Cathay Innovation’s San Francisco-based investor Brian Schwarzbach dives into the recommerce market, top areas drawing VC investment and some food for thought for founders building the space… […]
Behind the Term Sheet: How Inato is Solving the Massive Clinical Trial Access & Diversity Gap
Clinical trials are essential to medical innovation and the development of potentially life-saving drugs. But today, access is wildly off balance… […]